Status
Not yet recruiting
Phase
Phase 2
Enrollment
190
Locations
1
Results
Not posted
Publications
1
Study summary
The aim of this randomized controlled study is to compare the efficacy of three successive doses of a GnRH agonist ( administered 36 , 24 and 12 hours before oocyte retrieval ) with a single dose of a GnRH agonist ( administered 36 hours before oocyte retrieval ) in triggering ovulation in hyper-responders
Interventions
DRUG
GnRH agonist ( Triptorelin ) ( 0.2 mg / S.C ) is administered 36 hours before ovum pickup. Two additional doses of triptorelin ( 0.1 mg / S.C ) are administered subcutaneously 12 and 24 hours after the first dose of GnRH agonist.
DRUG
GnRH agonist ( Triptorelin ) ( 0.2 mg / S.C ) is administered 36 hours before ovum pickup.
Timeline
First posted
May 6, 2026
Study start
Jun 1, 2026
Primary completion
Dec 1, 2027
Study completion
Apr 1, 2028
Results posted
Not reported
Registry updated
May 11, 2026
Outcomes
Metaphase-II oocytes rate
Time frame · Ten to fifteen days after starting ovarian stimulation
Number of MII oocyte/ number of cumulus oocyte complex
Clinical pregnancy rate
Time frame · Five weeks after embryo transfer
Presence of intrauterine gestational sac detected by transvaginal ultrasound
Ongoing pregnancy Rate
Time frame · Eighteen weeks after embryo transfer
Pregnancies continued beyond 20 weeks gestation
Eligibility
Inclusion Criteria: * GnRH antagonist IVF cycle * Hyper-responders to induction of ovulation Exclusion Criteria: * Hypogonadotrophic hypogonadism * Endometriosis * History of recurrent abortion
Study locations
Egypt. Showing up to 24 locations stored in the fast local snapshot.
Bedaya Hospital
Giza, Egypt
Related trials
ECOG-ACRIN Cancer Research Group · Prostate Carcinoma
Phase 3
Active, not recruiting
27
2026-07
RenJi Hospital · Prostate Cancer · Prostate
Phase 2
Not yet recruiting
200
2026-07
Debiopharm International SA · Central Precocious Puberty
Phase 3
Active, not recruiting
56
2026-07
Mayo Clinic · Recurrent Castration-Sensitive Prostate Carcinoma · Recurrent Prostate Cancer
Phase 2
Recruiting
532
2026-07
Children's Oncology Group · Hematopoietic and Lymphatic System Neoplasm · Malignant Solid Neoplasm
Phase 3
Recruiting
60
2026-07
Ipsen · Early-stage Breast Cancer
Not applicable
Completed
450
2026-07
Rana McKay, MD · Prostate Cancer · BRCA1 Mutation
Phase 2
Active, not recruiting
32
2026-07
Li-jun Ding · Deep Infiltrating Endometriosis (DIE) · Infertility
Phase 4
Recruiting
120
2026-07
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.